<DOC>
	<DOCNO>NCT00103233</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vinorelbine , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Trastuzumab may also help vinorelbine work well make tumor cell sensitive drug . Giving vinorelbine together trastuzumab may effective treatment breast cancer . It yet know whether give vinorelbine together trastuzumab effective vinorelbine alone treat breast cancer . PURPOSE : This randomized phase III trial study vinorelbine trastuzumab see well work compare vinorelbine alone treat woman progressive metastatic breast cancer .</brief_summary>
	<brief_title>Vinorelbine With Without Trastuzumab Treating Women With Progressive Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare progression-free survival ( PFS ) woman HER2-positive progressive metastatic breast cancer treat vinorelbine without trastuzumab ( Herceptin® ) . - Compare overall survival time treatment failure patient treat regimen . - Compare toxicity regimens patient . - Compare response rate ( complete partial , confirm unconfirmed ) patient measurable disease treat regimen . - Correlate baseline circulate tumor cell ( CTC ) PFS , overall survival , disease progression status 9 week patient treat regimen . - Correlate 4-week CTC subsequent PFS overall survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive trastuzumab ( Herceptin® ) IV 90 minute vinorelbine IV 10 minute day 1 course 1 . Patients receive trastuzumab IV 30 minute vinorelbine IV 10 minute day 1 , 8 , 15 , 22 subsequent course . If trastuzumab discontinue due toxicity , patient may continue receive vinorelbine alone . - Arm II : Patients receive vinorelbine IV 10 minute day 1 , 8 , 15 , 22 . In arm , course repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month disease progression every 6 month 3 year . PROJECTED ACCRUAL : A total 292 patient ( 146 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Clinical evidence metastatic disease HER2positive tumor , indicate one follow method : HER2 gene amplification fluorescence situ hybridization HER2 protein overexpression ( 3+ ) immunohistochemistry Disease progression prior taxane therapy ( singleagent paclitaxel , docetaxel , taxanecontaining combination chemotherapy ) combination trastuzumab ( Herceptin® ) first secondline chemotherapy metastatic disease Patients receive maintenance therapy singleagent trastuzumab acheiving response stable disease prior taxane/trastuzumab combination therapy eligible provide disease progress Measurable nonmeasurable disease No effusion ascites site disease No leptomeningeal disease lymphatic pulmonary metastasis Brain metastasis allow provided disease stable &gt; 3 month completion prior radiotherapy brain Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Not specify Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Hepatic Bilirubin ≤ 2.0 mg/dL SGOT SGPT ≤ 2.5 time upper limit normal ( ULN ) ( &lt; 5 time ULN presence liver metastasis ) Alkaline phosphatase ≤ 3 time ULN ( &lt; 5 time ULN presence liver bone metastasis ) Renal Creatinine ≤ 2.0 mg/dL Calcium ≤ 11.0 mg/dL Cardiovascular No history significant symptomatic cardiac disease LVEF ≥ 50 % low limit normal MUGA ECG Other No preexist clinically significant ( ≥ grade 2 ) motor sensory neuropathy except abnormality due cancer No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics At least 28 day since prior trastuzumab No concurrent filgrastim ( GCSF ) Chemotherapy See Disease Characteristics No 2 prior chemotherapy regimens metastatic breast cancer Prior adjuvant/neoadjuvant chemotherapy allow , total 3 prior regimens No prior vinorelbine No prior chemotherapy progression taxane/trastuzumab regimen No prior cumulative dose &gt; 360 mg/m^2 anthracyclinebased chemotherapy Endocrine therapy No prior hormonal therapy progression taxane/trastuzumab regimen Prior exogenous hormonal therapy stage IV disease and/or adjuvant therapy allow Radiotherapy See Disease Characteristics No prior radiotherapy &gt; 50 % marrowbearing bone Surgery At least 4 week since prior major surgery ( 2 week minor surgery ) recover Other Concurrent bisphosphonates allow bone metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>